Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Boyett

Sports Medicine Athens, AL Doctor of Osteopathy

NPI 1326199530 CMS profile 571762

22454 Hwy 72 W, Suite 200, Athens, AL 35613

Open in the dashboard

General payments

$4,051

61 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Boyett of Athens, AL is reported in the CMS Open Payments database as having received $4,051 across 61 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 39th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $202 2
2024 General $2,398 27
2023 General $265 5
2022 General $197 1
2021 General $295 7
2020 General $422 10
2019 General $271 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Boyett
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Joseph Boyett were reported at $202. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Joseph Boyett Sports Medicine median Middle half National median
2019 $271 $1,176 $199–$4,249 $163
2020 $422 $708 $96–$2,890 $114
2021 $295 $1,213 $152–$3,994 $132
2022 $197 $1,230 $159–$3,998 $149
2023 $265 $584 $146–$2,836 $160
2024 $2,398 $628 $163–$3,168 $164
2025 $202 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Prime Surgical, LLC $1,347 7 payments
  2. Arthrex, Inc. $1,330 23 payments
  3. NuVasive, Inc. $830 17 payments
  4. Ferring Pharmaceuticals Inc. $124 1 payment
  5. DePuy Synthes Sales Inc. $109 2 payments
  6. Globus Medical, Inc. $98 1 payment
  7. Nevro Corp. $59 2 payments
  8. Saluda Medical Americas, Inc. $44 1 payment
  9. Medical Device Business Services, Inc. $33 2 payments
  10. Bioventus LLC $21 1 payment
  11. Other $56 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,055 55 payments
  2. Travel and Lodging $1,936 5 payments
  3. Entertainment $61 1 payment
Products named General payments · program years 2019–2025
  1. Pulse $197 1 payment
  2. Leverage $124 1 payment
  3. EUFLEXXA $124 1 payment
  4. XLIF $121 2 payments
  5. CORRIDOR $98 1 payment
  6. COHERE $96 1 payment
  7. MONOVISC $83 1 payment
  8. ORTHOVISC $83 1 payment
  9. POWER $46 1 payment
  10. Graft Delivery System $45 1 payment
  11. Other $467 22 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

1,647

Median for Orthopedic Surgery: 203

Drug cost

$17,188

Median for Orthopedic Surgery: $1,433

Branded share of claims

24.5%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 16 $8,792
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 320 $1,947
Ondansetron Hcl Generic 264 $1,371
Oxycodone Hcl Generic 234 $1,021
Methocarbamol Generic 145 $946
Diclofenac Sodium Generic 31 $531
Meloxicam Generic 212 $520
Methylprednisolone Generic 50 $356
Tramadol Hcl Generic 119 $327
Ibuprofen Generic 82 $261

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 157 billing codes

Paid by Medicare

$336,825

Of which drugs: $34,951

Medicare patients

608

Average age 75

Services billed

9,382

380 women, 228 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 34%
Ischemic heart disease 32%
Depression 30%
Chronic kidney disease 26%
Osteoporosis 20%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 Office 62 4,112 $28,129
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 258 1,790 $1,296

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

61 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record